On November 1, 2024, Daniel Moorhead, Chief Financial Officer of Zynex Inc (ZYXI, Financial), executed a sale of 10,000 shares of the company at a price of $8.59 per share. This transaction was filed on November 4, 2024, as reported in the SEC Filing. Following this sale, the insider now owns 44,878 shares of Zynex Inc.
Zynex Inc, listed under the symbol ZYXI, operates in the medical technology sector, specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring. The company's innovative product line aims to improve health outcomes and quality of life for patients.
Over the past year, Daniel Moorhead has sold a total of 25,000 shares and has not purchased any shares. This recent transaction is part of a broader trend observed within Zynex Inc, where insider activity over the past year includes 1 insider buy and 4 insider sells.
The shares of Zynex Inc were trading at $8.59 on the day of the transaction, giving the company a market cap of $254.764 million. The price-earnings ratio of the stock stands at 57.14, which is above both the industry median of 19.82 and the historical median for the company.
According to the GF Value, Zynex Inc is significantly undervalued with a price-to-GF-Value ratio of 0.65, based on a GF Value of $13.23. The GF Value is calculated considering historical trading multiples, an adjustment factor based on past returns and growth, and future business performance estimates.
This insider sale might interest investors tracking insider behaviors as an indicator of the company's future performance and valuation adjustments. The transaction details and the company's valuation metrics provide a comprehensive view of the insider's recent financial decisions and the company's current market standing.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
